{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:42:38Z","timestamp":1760784158363},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40256-016-0188-x","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T21:38:36Z","timestamp":1472852316000},"page":"453-460","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Macitentan: A Review in Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"16","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"issue":"25 Suppl D","key":"188_CR1","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","volume":"62","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl D):D42\u201350.","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"188_CR2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","volume":"336","author":"LJ Rubin","year":"1997","unstructured":"Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336(2):111\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"188_CR3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67\u2013119.","journal-title":"Eur Heart J"},{"issue":"4","key":"188_CR4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S2213-2600(15)00542-1","volume":"4","author":"MM Hoeper","year":"2016","unstructured":"Hoeper MM, McLaughlin VV, Dalaan AM, et al. Treatment of pulmonary hypertension. Lancet Respir Med. 2016;4(4):323\u20136.","journal-title":"Lancet Respir Med."},{"issue":"24","key":"188_CR5","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","volume":"328","author":"A Giaid","year":"1993","unstructured":"Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"188_CR6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","volume":"61","author":"N Gali\u00e9","year":"2004","unstructured":"Gali\u00e9 N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61(2):227\u201337.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"188_CR7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14740338.2014.859674","volume":"13","author":"J Dingemanse","year":"2014","unstructured":"Dingemanse J, Sidharta PN, Maddrey WC, et al. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014;13(3):391\u2013405.","journal-title":"Expert Opin Drug Saf."},{"key":"188_CR8","unstructured":"Actelion Pharmaceuticals US Inc. Opsumit\u00ae (macitentan) tablets, for oral use: US prescribing information. 2016. http:\/\/opsumit.com\/ . Accessed 8 Aug 2016."},{"key":"188_CR9","unstructured":"European Medicines Agency. Opsumit (macitentan): EU summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 8 Aug 2016."},{"issue":"3","key":"188_CR10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","volume":"327","author":"M Iglarz","year":"2008","unstructured":"Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736\u201345.","journal-title":"J Pharmacol Exp Ther"},{"issue":"17","key":"188_CR11","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1021\/jm3009103","volume":"55","author":"MH Bolli","year":"2012","unstructured":"Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N\u2032-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55(17):7849\u201361.","journal-title":"J Med Chem"},{"issue":"10","key":"188_CR12","doi-asserted-by":"crossref","first-page":"e47662","DOI":"10.1371\/journal.pone.0047662","volume":"7","author":"J Gatfield","year":"2012","unstructured":"Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7(10):e47662.","journal-title":"PLoS One"},{"issue":"6","key":"188_CR13","doi-asserted-by":"crossref","first-page":"L523","DOI":"10.1152\/ajplung.00129.2014","volume":"308","author":"T Shinohara","year":"2015","unstructured":"Shinohara T, Sawada H, Otsuki S, et al. Macitentan reverses early obstructive pulmonary vasculopathy in rats: early intervention in overcoming the survivin-mediated resistance to apoptosis. Am J Physiol Lung Cell Mol Physiol. 2015;308(6):L523\u201338.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"5","key":"188_CR14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/FJC.0000000000000296","volume":"66","author":"M Iglarz","year":"2015","unstructured":"Iglarz M, Landskroner K, Bauer Y, et al. Comparison of macitentan and bosentan on right ventricular remodeling in a rat model of non-vasoreactive pulmonary hypertension. J Cardiovasc Pharmacol. 2015;66(5):457\u201367.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"188_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.lfs.2014.02.018","volume":"118","author":"M Iglarz","year":"2014","unstructured":"Iglarz M, Bossu A, Wanner D, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014;118(2):333\u20139.","journal-title":"Life Sci"},{"issue":"Suppl 57","key":"188_CR16","first-page":"P4060","volume":"42","author":"O Sitbon","year":"2013","unstructured":"Sitbon O, Channick R, Delcroix M, et al. Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) [abstract no. 3863 plus poster]. Eur Respir J. 2013;42(Suppl 57):P4060.","journal-title":"Eur Respir J"},{"issue":"9","key":"188_CR17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"188_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pupt.2014.04.007","volume":"29","author":"N Lindegger","year":"2014","unstructured":"Lindegger N, Sidharta PN, Reseski K, et al. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects. Pulm Pharmacol Ther. 2014;29(1):41\u20138.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"188_CR19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40262-015-0322-y","volume":"55","author":"R Kanter de","year":"2016","unstructured":"de Kanter R, Sidharta PN, Delahaye S, et al. Physiologically-based pharmacokinetic modeling of macitentan: prediction of drug-drug interactions. Clin Pharmacokinet. 2016;55(3):369\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"188_CR20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/jcph.152","volume":"53","author":"PN Sidharta","year":"2013","unstructured":"Sidharta PN, van Giersbergen PLM, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol. 2013;53(11):1131\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"188_CR21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/00498254.2012.664665","volume":"42","author":"S Bruderer","year":"2012","unstructured":"Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 2012;42(9):901\u201310.","journal-title":"Xenobiotica"},{"issue":"5\u20136","key":"188_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000351704","volume":"91","author":"S Bruderer","year":"2013","unstructured":"Bruderer S, Marjason J, Sidharta PN, et al. Pharmacokinetics of macitentan in Caucasian and Japanese subjects: the influence of ethnicity and sex. Pharmacology. 2013;91(5\u20136):331\u20138.","journal-title":"Pharmacology"},{"issue":"5","key":"188_CR23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40256-014-0081-4","volume":"14","author":"LY Ahn","year":"2014","unstructured":"Ahn LY, Kim SE, Yi S, et al. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects. Am J Cardiovasc Drugs. 2014;14(5):377\u201385.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"3","key":"188_CR24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jcph.193","volume":"54","author":"PN Sidharta","year":"2014","unstructured":"Sidharta PN, Lindegger N, Ul\u010d I, et al. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol. 2014;54(3):291\u2013300.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"188_CR25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/s12248-011-9316-3","volume":"14","author":"S Bruderer","year":"2012","unstructured":"Bruderer S, \u00c4\u00e4nismaa P, Homery M-C, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2012;14(1):68\u201378.","journal-title":"AAPS J."},{"issue":"8","key":"188_CR26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","volume":"52","author":"J Atsmon","year":"2013","unstructured":"Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013;52(8):685\u201392.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"188_CR27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jcph.639","volume":"56","author":"N Hurst","year":"2016","unstructured":"Hurst N, Pellek M, Dingemanse J, et al. Lack of pharmacokinetic interactions between macitentan and a combined oral contraceptive in healthy female subjects. J Clin Pharmacol. 2016;56(6):669\u201374.","journal-title":"J Clin Pharmacol"},{"key":"188_CR28","first-page":"A4802","volume":"185","author":"PN Sidharta","year":"2012","unstructured":"Sidharta PN, van Giersbergen PLM, Wolzt M, et al. Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects [abstract]. Am J Respir Crit Care Med. 2012;185:A4802.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"188_CR29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40261-014-0207-0","volume":"34","author":"PN Sidharta","year":"2014","unstructured":"Sidharta PN, Dietrich H, Dingemanse J. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. Clin Drug Investig. 2014;34(8):545\u201352.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"188_CR30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/jpet.114.214106","volume":"350","author":"A Treiber","year":"2014","unstructured":"Treiber A, \u00c4\u00e4nismaa P, de Kanter R, et al. Macitentan does not interfere with hepatic bile salt transport. J Pharmacol Exp Ther. 2014;350(1):130\u201343.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"188_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2014.07.013","volume":"3","author":"RN Channick","year":"2015","unstructured":"Channick RN, Delcroix M, Ghofrani H-A, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3(1):1\u20138.","journal-title":"JACC Heart Fail."},{"key":"188_CR32","first-page":"A4783","volume":"189","author":"RN Channick","year":"2014","unstructured":"Channick RN, Delcroix M, Galie N, et al. The effect of macitentan on long-term outcomes in patients with pulmonary arterial hypertension by WHO functional class: data from the randomized controlled SERAPHIN study [abstract no. C93 plus poster]. Am J Respir Crit Care Med. 2014;189:A4783.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"188_CR33","first-page":"10","volume":"35","author":"N Galie","year":"2014","unstructured":"Galie N, Delcroix M, Ghofrani H-A, et al. Anticoagulant therapy does not influence long-term outcomes in patients with pulmonary arterial hypertension (PAH): insights from the randomised controlled SERAPHIN trial of macitentan [abstract no. 65]. Eur Heart J. 2014;35(Suppl 1):10.","journal-title":"Eur Heart J"},{"issue":"Suppl 58","key":"188_CR34","first-page":"3419","volume":"44","author":"O Sitbon","year":"2014","unstructured":"Sitbon O, Channick RN, Delcroix M, et al. Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) [abstract]. Eur Respir J. 2014;44(Suppl 58):3419.","journal-title":"Eur Respir J"},{"issue":"6","key":"188_CR35","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1183\/13993003.00364-2015","volume":"46","author":"G Simonneau","year":"2015","unstructured":"Simonneau G, Channick RN, Delcroix M, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015;46(6):1711\u201320.","journal-title":"Eur Respir J"},{"issue":"Suppl 2","key":"188_CR36","first-page":"31","volume":"44","author":"P Youssef","year":"2014","unstructured":"Youssef P, Galie N, Perchenet L, et al. Effect of macitentan on health-related quality of life (HRQOL) in pulmonary arterial hypertension (PAH): results from the SERAPHIN randomised controlled trial [abstract no. ARA-P76]. Intern Med J. 2014;44(Suppl 2):31.","journal-title":"Intern Med J."},{"key":"188_CR37","first-page":"A7396","volume":"193","author":"NH Kim","year":"2016","unstructured":"Kim NH, Chin KM, Muros-Le Rouzic E, et al. OPsumit\u00ae USers Registry (OPUS): insights into the safety and tolerability of Opsumit\u00ae [abstract no. P1031 plus poster]. Am J Respir Crit Care Med. 2016;193:A7396.","journal-title":"Am J Respir Crit Care Med"},{"key":"188_CR38","doi-asserted-by":"crossref","unstructured":"Safdar Z, Thakur A, Frost A. Edema in patient switched to macitentan from bosentan and ambrisentan in pulmonary arterial hypertension [abstract]. Chest. 2015;148(4):939A\u2013B.","DOI":"10.1378\/chest.2280587"},{"issue":"Suppl 1","key":"188_CR39","first-page":"458","volume":"36","author":"IM Blok","year":"2015","unstructured":"Blok IM, Van Riel ACMJ, Schuuring MJ, et al. Macitentan superior to bosentan in pulmonary arterial hypertension due to congenital heart disease? [abstract no. P2658]. Eur Heart J. 2015;36(Suppl 1):458.","journal-title":"Eur Heart J"},{"issue":"25 Suppl D","key":"188_CR40","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","volume":"62","author":"N Gali\u00e8","year":"2013","unstructured":"Gali\u00e8 N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl D):D60\u201372.","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"188_CR41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40264-015-0275-y","volume":"38","author":"M Aversa","year":"2015","unstructured":"Aversa M, Porter S, Granton J. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension. Drug Saf. 2015;38(5):419\u201335.","journal-title":"Drug Saf"},{"issue":"9","key":"188_CR42","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834\u201344.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-016-0188-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T05:31:15Z","timestamp":1718775075000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-016-0188-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1007\/s40256-016-0188-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]}}}